New results demonstrate efficacy of Stretta RF Therapy in GERD- Mederi Therapeutics

Mederi Therapeutics announced new 10-year data which shows efficacy of Stretta RF Therapy in three specific types of non-classical GERD patients: those with high BMI, those with respiratory symptoms of GERD, and those suffering from recurring GERD after anti-reflux surgery. The data examined challenging GERD patient subsets that were included in his published 10-year study, and demonstrated that each of these patient populations achieved the primary outcomes of long-term symptom relief, reduced medication use, and patient satisfaction.

Stretta is effective in the treatment of medically refractory GERD, independent of BMI. 73 patients comprising three subpopulations of BMI (Normal, Overweight, and Obese) were studied. At 10-year follow-up, regardless of BMI, all parameters demonstrated statistically significant improvement. Stretta is effective in laryngopharyngeal reflux (LPR). 99 refractory LPR and non-LPR patients were studied. At 10-year follow-up, all parameters demonstrated statistically significant improvement across the entire respondent cohort. In patients with refractory GERD after a laparoscopic Nissen fundoplication (LNF), Stretta results in sustained improvement with near equivalence and slightly better outcomes than the non-LNF cohort. 18 refractory LNF (RLNF+S) and 81 standard refractory GERD patients were studied. At 10-year follow-up, both patient subsets demonstrated statistically significant improvement in primary outcomes. New data were presented at Digestive Disease Week (DDW).